QUOTE AND NEWS
FiercePharma  2 hrs ago  Comment 
Novartis is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng's claims that the Swiss drugmaker downplayed the bone...
The Economic Times  May 14  Comment 
Novartis India on Tuesday reported a 25.82 per cent dip in its net profit to Rs 24.41 crore for the quarter ended March 31, 2013.
The Hindu Business Line  May 13  Comment 
Novartis India has announced the next edition of the Novartis Biotechnology Leadership Camp (BioCamp) taking place in Hyderabad from July 8-10, 2013.   BioCamp is a seminar orga...
MedPage Today  May 10  Comment 
(MedPage Today) -- Ilaris, a monoclonal antibody targeting interleukin-1beta, has been approved for the treatment of systemic juvenile idiopathic arthritis), the manufacturer announced.
FiercePharma  May 10  Comment 
Novartis has grabbed one of two new indications it was shooting for with its rare disease drug Ilaris, one step toward turning the drug into a blockbuster.
Forbes  May 9  Comment 
In recent years, pharmaceutical companies have faced criminal investigations and charges in regard to alleged off-label marketing of prescription drugs and kickbacks to doctors.  For this reason, the filing last month of two civil cases against...
The Economic Times  May 9  Comment 
Drug major Novartis India said its Swiss promoter Novartis AG has appointed Citigroup Capital Markets as the broker for the proposed share sale.
FierceBiotech  May 6  Comment 
Ever since the FDA started to anoint a short list of drug candidates as "breakthrough" therapies deserving of swift regulatory reviews, the industry has been trying to puzzle out one important question: What does it mean?
FierceBiotech  May 3  Comment 
Novartis has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant.




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki